real-time news and commentary for investors
Tuesday, Sep 10
Synta Pharmaceutical launches its proprietary Small Molecule Hsp90-inhibitor Drug Conjugate platform
- Synta Pharmaceuticals (SNTA) says it's launching its Hsp90-inhibitor Drug Conjugate platform, with the intention of creating a new class of anti-cancer therapies.
- The objective is to create novel drug conjugates that exploit Hsp90 biology to selectively deliver potent anti-cancer payloads to cancer cells.
- The drug developer expects to launch its first investigational new drug in next 18 months.